Sunday, July 13, 2025
spot_img

Covaxin has excellent safety record, says Bharat Biotech

Date:

Share post:

spot_imgspot_img

Shillong, May 2: Bharat Biotech on Thursday said that its Covid-19 vaccine Covaxin has an excellent safety record without any vaccine-associated incidents of blood clots, thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc, as it was developed with a single-minded focus on safety first, followed by efficacy.

The Hyderabad-based company issued a statement amid questions being raised in some quarters over the safety of Covid vaccines after global pharmaceutical manufacturer AstraZeneca admitted that its Covid vaccine Covishield, developed by researchers from Oxford University, can cause a rare side effect of blood clotting and low platelet count after immunisation.

As many as 175 crore doses of Covishield, developed by AstraZeneca and manufactured by Pune-based Serum Institute, were reportedly administered in India.

Bharat Biotech mentioned that Covaxin was the only Covid-19 vaccine in the Indian government’s Covid-19 immunisation programme to have conducted efficacy trials in India.

“Covaxin was evaluated in more than 27,000 subjects as part of its licensure process. It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects,” the vaccine manufacturer said.

The safety of Covaxin was also evaluated by the Ministry of Health.

“Ongoing safety monitoring (pharmacovigilance) was continued throughout the product life cycle of Covaxin. All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin without any vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc.,” it said.

“As seasoned innovators and product developers, the Bharat Biotech team was well aware that, while the efficacy of Covid-19 vaccines may be short-lived, the impact on patient safety could last a lifetime. Hence safety is the primary focus for all our vaccines,” it added. (IANS)

spot_imgspot_img

Related articles

Sorkari, kamtangko ka·na chu·sokjaode sakgipinna pakwatbo: VPP

SHILLONG: Voice of the People Party (VPP)-ni chief Ardent Miller Basaiawmoit, NPP-chi dilenggipa sorkariko kamtangko name dake ka·na...

Chokpot jolni neng·nikarangko namatna CSO, songni dilgiparang bakrima

SHILLONG: Ramani obostarang namjani bidingo, gipin jatrangko songrangona skatang napna on·engani bidingrango sorkariko nirokatchina gita Civil society organisation,...

Sitharaman, Meghalaya-ni $30 economy-ona sokna re·mikkanganio dakchakna agana

SHILLONG: Ma·mongni Finance Minister Nirmala Sitharaman, Meghalaya a·dokni Health sector-o namen tang·doaniko nike de·mittelaha. Mongsongbate Meghalaya-o Maternity Mortality...

Game ge·e cha·giparangko bilakdapatna IPDM training-ko ICAR-KVK ong·ata

TURA: ICAR - Krishi Vigyan Kendra (KVK), West Garo Hills, Dalu Block-ni Marapara songo NICRA project-ni ning·o method-ko...